India finds 5.5% of drugs substandard; New bill aims to speed FDA approvals;

> Questions in the Indian parliament as to whether Indian regulators have a handle on substandard and counterfeit pharmaceuticals being made there prompted a minister to report that in the first half of 2011, 5.5% of the 26,000 drugs tested were substandard. Story

> The FDA has filed a document with the Federal Register reiterating its estimate that electronic registration of drug manufacturers and their products, and the additional information sought, should add an average burden of only 4½ hours to the process. It will accept comments, made by fax, until April 25. Filing

> Creating a new wrinkle for cosmetics manufacturers, the director of the FDA's Center for Food Safety and Applied Nutrition told a House subcommittee that so-called "cosmeceuticals" that contain active ingredients like retinol may need to be regulated like drugs. Story

> Members from both parties in Congress have filed a new bill that would speed FDA approvals, this time for so-called breakthrough drugs, any drug aimed at serious conditions or diseases where preliminary clinical trials indicate a substantial improvement over existing therapies. Story

> Novasep says it is opening a 2,000 square meter facility in Shanghai to expand production of its purification technologies and integrated processes in batch and continuous membrane filtration, ion exchange and chromatography. Story

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.